Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2566)

VOLUNTARY ANNOUNCEMENT
INVESTIGATIONAL NEW DRUG APPLICATION OF JY47 INJECTION OBTAINED CLINICAL TRIAL APPROVAL BY THE NMPA

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders (the "**Shareholders**") and potential investors of the Group about the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the investigational new drug (IND) application of the JY47 Injection (the "**Product**"), independently developed by the Group, has obtained clinical trial approval by the National Medical Products Administration of the People's Republic of China (the "**NMPA**"), with the indication being metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.

The Product is a monoclonal antibody injection targeting SIRPα developed by the Group. SIRPα is a classical inhibitory receptor that can bind to its ligand CD47 with high affinity. Research indicates that the CD47-SIRPα signaling pathway plays an important role in the immune regulation associated with metabolic diseases. SIRP antagonists can exert a positive impact on the progression of metabolic diseases by regulating immune cell function and improving the tissue microenvironment and metabolic homeostasis. It has demonstrated promising therapeutic potential in in vitro organoid models and in vivo disease models for MASH.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, March 17, 2026

As at the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.